Mar 19 |
Centogene, Takeda extend diagnostic partnership
|
Mar 19 |
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
|
Mar 14 |
Japan’s Stock Market Is Back, and It Isn’t Too Late to Buy
|
Mar 13 |
Takeda buoyed by mid-stage trial for immune disorder treatment mezagitamab
|
Mar 13 |
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
|
Mar 12 |
Pfizer succeeds in Phase 3 trial for Adcetris in new lymphoma condition
|
Mar 11 |
Takeda Pharmaceutical Co. (TAK) Upgraded to Buy: What Does It Mean for the Stock?
|
Mar 11 |
TAK or STVN: Which Is the Better Value Stock Right Now?
|
Mar 5 |
Alexandria (ARE) Announces Lease Extension at Kendall Square
|
Mar 5 |
Takeda Pharmaceutical: Eohilia's FDA Approval Brings Tailwinds
|